TSLP

Summary

TSLP (thymic stromal lymphopoietin, HGNC:30743) is a protein-coding gene on chromosome 5q22.1, encoding Thymic stromal lymphopoietin (Q969D9). Cytokine that induces the release of T-cell-attracting chemokines from monocytes and, in particular, enhances the maturation of CD11c(+) dendritic cells.

This gene encodes a hemopoietic cytokine proposed to signal through a heterodimeric receptor complex composed of the thymic stromal lymphopoietin receptor and the IL-7R alpha chain. It mainly impacts myeloid cells and induces the release of T cell-attracting chemokines from monocytes and enhances the maturation of CD11c(+) dendritic cells. The protein promotes T helper type 2 (TH2) cell responses that are associated with immunity in various inflammatory diseases, including asthma, allergic inflammation and chronic obstructive pulmonary disease. The protein is therefore considered a potential therapeutic target for the treatment of such diseases. In addition, the shorter (predominant) isoform is an antimicrobial protein, displaying antibacterial and antifungal activity against B. cereus, E. coli, E. faecalis, S. mitis, S. epidermidis, and C. albicans. Alternative splicing of this gene results in multiple transcript variants.

Source: NCBI Gene 85480 — RefSeq curated summary.

At a glance

• GWAS associations: 60 (top 1% of genes corpus-wide)
• Clinical variants (ClinVar): 31 total
• GTEx eGene: eQTL in 44 tissues, sQTL in 0 (q < 0.05)
• Drug target: yes — 1 curated mechanism-of-action drug
• Approved drugs (ChEMBL mechanism of action): 1 — Tezepelumab
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 1.43 (unconstrained)
• MANE Select transcript: NM_033035

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30743
Approved symbol	TSLP
Name	thymic stromal lymphopoietin
Location	5q22.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000145777
Ensembl biotype	protein_coding
OMIM	607003
Entrez	85480

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

MANE Select: ENST00000344895

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 3

ENST00000344895, ENST00000379706, ENST00000420978

RefSeq mRNA: 2 — MANE Select: NM_033035 NM_033035, NM_138551

CCDS: CCDS4101

Canonical transcript exons

ENST00000344895 — 4 exons

Exon	Start	End
ENSE00002211371	111072888	111072932
ENSE00002286480	111073511	111073645
ENSE00002314243	111071713	111072061
ENSE00004780085	111075946	111078026

Expression profiles

Bgee: expression breadth ubiquitous, 173 present calls, max score 80.54.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.6320 / max 439.8223, expressed in 1034 samples.

Highest expression (Bgee): epithelial cell of pancreas, gall bladder, cartilage tissue, lobe of liver, heart right ventricle.

Genetic regulation across tissues (GTEx eQTL / sQTL)

TSLP is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 44 tissues and its splicing (sQTL) in 0 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 44 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Testis	eqtl	8.1e-104	+0.97	5:111069977:A:G
Adipose Subcutaneous	eqtl	1.8e-80	-0.65	5:111073369:C:G
Artery Tibial	eqtl	1.9e-66	-0.67	5:111073369:C:G
Nerve Tibial	eqtl	5.6e-60	-0.73	5:111073369:C:G
Skin Sun Exposed Lower leg	eqtl	2.4e-53	-0.61	5:111073007:C:T
Thyroid	eqtl	9.7e-50	-0.59	5:111069977:A:G
Esophagus Mucosa	eqtl	3.1e-46	-0.60	5:111073369:C:G
Adipose Visceral Omentum	eqtl	4.3e-44	-0.55	5:111073369:C:G
Adrenal Gland	eqtl	2.2e-40	-0.93	5:111073369:C:G
Skin Not Sun Exposed Suprapubic	eqtl	8.7e-39	-0.48	5:111073369:C:G
Breast Mammary Tissue	eqtl	4.1e-30	-0.49	5:111077791:G:A
Brain Caudate basal ganglia	eqtl	2.7e-27	-0.75	5:111073369:C:G
Artery Aorta	eqtl	3.0e-24	-0.52	5:111073369:C:G
Cells Cultured fibroblasts	eqtl	2.4e-20	-0.23	5:111069977:A:G
Colon Sigmoid	eqtl	3.4e-19	-0.51	5:111073369:C:G
Spleen	eqtl	1.8e-18	-0.72	5:111073007:C:T
Brain Hypothalamus	eqtl	4.8e-18	-0.71	5:111073369:C:G
Brain Cerebellar Hemisphere	eqtl	1.3e-15	-0.63	5:111069977:A:G
Brain Putamen basal ganglia	eqtl	2.1e-15	-0.77	5:111073369:C:G
Brain Spinal cord cervical c-1	eqtl	3.7e-15	-0.65	5:111073369:C:G

FANTOM5 promoters

7 alternative TSS:

Promoter ID	TPM avg	Samples expressed
57959	3.7983	924
57960	0.6796	343
57958	0.4197	231
57961	0.2970	149
57957	0.2571	43
203651	0.1772	81
57956	0.0031	1

Top tissues by expression

showing 100 of 245 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
epithelial cell of pancreas	CL:0000083	80.54	gold quality
gall bladder	UBERON:0002110	79.34	gold quality
cartilage tissue	UBERON:0002418	78.59	gold quality
right lobe of liver	UBERON:0001114	75.54	gold quality
heart right ventricle	UBERON:0002080	74.97	gold quality
left ventricle myocardium	UBERON:0006566	73.83	gold quality
heart left ventricle	UBERON:0002084	73.64	gold quality
cardiac ventricle	UBERON:0002082	73.34	gold quality
liver	UBERON:0002107	73.31	gold quality
esophagus squamous epithelium	UBERON:0006920	73.23	gold quality
esophagus mucosa	UBERON:0002469	71.66	gold quality
apex of heart	UBERON:0002098	70.98	gold quality
esophagus	UBERON:0001043	69.49	gold quality
heart	UBERON:0000948	69.33	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	68.91	gold quality
urinary bladder	UBERON:0001255	68.83	gold quality
lower esophagus mucosa	UBERON:0035834	68.66	gold quality
prostate gland	UBERON:0002367	67.65	gold quality
right coronary artery	UBERON:0001625	67.51	gold quality
lower esophagus	UBERON:0013473	67.19	gold quality
lower esophagus muscularis layer	UBERON:0035833	67.19	gold quality
right atrium auricular region	UBERON:0006631	66.62	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	66.54	gold quality
cardiac atrium	UBERON:0002081	65.66	gold quality
seminal vesicle	UBERON:0000998	65.13	gold quality
hindlimb stylopod muscle	UBERON:0004252	65.09	gold quality
myocardium	UBERON:0002349	64.57	silver quality
descending thoracic aorta	UBERON:0002345	64.48	gold quality
vermiform appendix	UBERON:0001154	64.46	gold quality
popliteal artery	UBERON:0002250	64.39	gold quality
tibial artery	UBERON:0007610	64.39	gold quality
left coronary artery	UBERON:0001626	64.31	gold quality
adipose tissue of abdominal region	UBERON:0007808	64.27	gold quality
adipose tissue	UBERON:0001013	64.25	gold quality
omental fat pad	UBERON:0010414	64.25	gold quality
peritoneum	UBERON:0002358	64.19	gold quality
aorta	UBERON:0000947	64.07	gold quality
ascending aorta	UBERON:0001496	63.98	gold quality
thoracic aorta	UBERON:0001515	63.97	gold quality
gastrocnemius	UBERON:0001388	63.56	gold quality
mucosa of sigmoid colon	UBERON:0004993	63.52	gold quality
mucosa of transverse colon	UBERON:0004991	63.47	gold quality
muscle of leg	UBERON:0001383	63.36	gold quality
palpebral conjunctiva	UBERON:0001812	63.31	gold quality
coronary artery	UBERON:0001621	63.25	gold quality
islet of Langerhans	UBERON:0000006	63.01	gold quality
vagina	UBERON:0000996	62.69	gold quality
thoracic mammary gland	UBERON:0005200	62.43	gold quality
mammary gland	UBERON:0001911	62.10	gold quality
urethra	UBERON:0000057	61.99	gold quality
ectocervix	UBERON:0012249	61.56	gold quality
rectum	UBERON:0001052	61.06	gold quality
upper lobe of left lung	UBERON:0008952	61.03	gold quality
mucosa of stomach	UBERON:0001199	60.96	gold quality
subcutaneous adipose tissue	UBERON:0002190	60.91	gold quality
muscle layer of sigmoid colon	UBERON:0035805	60.82	gold quality
upper lobe of lung	UBERON:0008948	60.75	gold quality
smooth muscle tissue	UBERON:0001135	60.60	gold quality
minor salivary gland	UBERON:0001830	59.68	gold quality
mammary duct	UBERON:0001765	59.63	silver quality
epithelium of mammary gland	UBERON:0003244	59.62	silver quality
uterine cervix	UBERON:0000002	59.43	gold quality
right lung	UBERON:0002167	59.38	gold quality
caecum	UBERON:0001153	59.19	gold quality
lung	UBERON:0002048	59.02	gold quality
endocervix	UBERON:0000458	59.01	gold quality
colon	UBERON:0001155	58.72	gold quality
colonic mucosa	UBERON:0000317	58.70	gold quality
large intestine	UBERON:0000059	58.61	gold quality
mouth mucosa	UBERON:0003729	57.96	gold quality
lower lobe of lung	UBERON:0008949	57.89	silver quality
left adrenal gland	UBERON:0001234	57.78	gold quality
left testis	UBERON:0004533	57.71	gold quality
intestine	UBERON:0000160	57.42	gold quality
epithelium of nasopharynx	UBERON:0001951	57.36	silver quality
colonic epithelium	UBERON:0000397	57.23	silver quality
saliva-secreting gland	UBERON:0001044	57.21	gold quality
right testis	UBERON:0004534	57.19	gold quality
transverse colon	UBERON:0001157	57.17	gold quality
nasal cavity mucosa	UBERON:0001826	57.13	gold quality
skin of hip	UBERON:0001554	56.78	silver quality
testis	UBERON:0000473	56.38	gold quality
deltoid	UBERON:0001476	56.08	silver quality
muscle tissue	UBERON:0002385	56.01	gold quality
left adrenal gland cortex	UBERON:0035825	55.87	gold quality
skeletal muscle tissue	UBERON:0001134	55.34	gold quality
body of stomach	UBERON:0001161	55.34	gold quality
fundus of stomach	UBERON:0001160	55.29	gold quality
small intestine	UBERON:0002108	55.24	gold quality
small intestine Peyer’s patch	UBERON:0003454	55.24	gold quality
mammalian vulva	UBERON:0000997	54.94	silver quality
cardiac muscle of right atrium	UBERON:0003379	54.84	gold quality
skin of leg	UBERON:0001511	54.81	gold quality
body of uterus	UBERON:0009853	54.72	gold quality
duodenum	UBERON:0002114	54.67	gold quality
mucosa of paranasal sinus	UBERON:0005030	54.66	gold quality
skin of abdomen	UBERON:0001416	54.61	gold quality
metanephros cortex	UBERON:0010533	54.47	gold quality
right adrenal gland	UBERON:0001233	54.40	gold quality
adrenal cortex	UBERON:0001235	54.25	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

HPA expression

RNA tissue specificity: Tissue enhanced

55 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM
Urinary bladder	tissue	11.2
Liver	tissue	10.8
Gallbladder	tissue	8.2
Prostate	tissue	5.8
Heart muscle	tissue	4.0
Seminal vesicle	tissue	3.8
Esophagus	tissue	3.1
Thyroid gland	tissue	2.5
Vagina	tissue	1.9
Adipose tissue	tissue	1.5
Breast	tissue	1.4
Testis	tissue	1.4
Skeletal muscle	tissue	1.3
Tongue	tissue	1.3
Appendix	tissue	1.2
Cervix	tissue	1.1
Stomach 1	tissue	1.1
Rectum	tissue	0.9
Lung	tissue	0.9
Colon	tissue	0.8
Endometrium 1	tissue	0.8
Small intestine	tissue	0.7
Salivary gland	tissue	0.6
Duodenum	tissue	0.6
Adrenal gland	tissue	0.6
Skin 1	tissue	0.5
Smooth muscle	tissue	0.5
Medulla oblongata	tissue	0.5
Tonsil	tissue	0.5
Pituitary gland	tissue	0.4
Lymph node	tissue	0.4
Parathyroid gland	tissue	0.4
Spinal cord	tissue	0.4
Ovary	tissue	0.3
Spleen	tissue	0.3
Kidney	tissue	0.3
Fallopian tube	tissue	0.3
Pancreas	tissue	0.2
Epididymis	tissue	0.2
Putamen	tissue	0.2
Nucleus accumbens	tissue	0.2
Choroid plexus	tissue	0.2
Hippocampus	tissue	0.2
Retrosplenial cortex	tissue	0.2
Cerebral cortex	tissue	0.1
Basal ganglia	tissue	0.1
Placenta	tissue	0.1
Cerebellum	tissue	0.1
Substantia nigra	tissue	0.1
Locus coeruleus	tissue	0.1
Thymus	tissue	0.1
Hippocampal formation	tissue	0.1
Postcentral gyrus	tissue	0.1
Caudate putamen	tissue	0.1
Occipital cortex	tissue	0.1

Brain sub-regions (HPA Brain Atlas): detected in 164; highest nTPM — Anterior thalamic nucleus, ventral (2.1), Blood vessel (1.3), Area postrema (0.5), Corpus callosum, genu (white matter) (0.5), Medial dorsal thalamic nucleus (0.5).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AP1, BCL11B, HAND2, IRF3, JUN, NFKB1, NFKB, RARG, RELA, VDR

miRNA regulators (miRDB)

Targeting TSLP by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 114 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502

Functional genomics

gnomAD constraint: pLI 5.91e-05, LOEUF 1.43, missense Z -0.549 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000344895 — one region, missense o/e 1.17.

Literature-anchored findings (GeneRIF, showing 40)

• This protein is a hemopoietic cytokine that signals through a heterodimeric receptor complex consisting of the human TSLP receptor and the IL-7R alpha-chain. (PMID:11418668)
• Epithelial cell-derived TSLP not only potently activates dendritic cells, but also endows DCs with the ability to polarize naive T cells to produce proallergic Th2 cytokines. (PMID:12055625)
• Data suggest that CD40L-expressing cells may act in combination with thymic stromal lymphopoietin to amplify and sustain pro-allergic responses. (PMID:12707303)
• Reviewer points out that epithelial- and stromal-cell-derived TSLP may represent one of the factors initiating allergic responses, and that it could be a target for a curative therapeutic approach to allergy. (PMID:14999427)
• TSLP is a major regulatory cytokine for CD40 ligand-induced IL-12 production by DCs, and TSLP-activated DCs could promote the persistence of Th2 inflammation even in the presence of IL-12-inducing signals (PMID:15741223)
• Elevated bronchial mucosal expression of TSLP is implicated in asthma pathogenesis; its action is partly through selective development and retention, or recruitment of T helper type 2, not Th1, receptor-bearing cells. (PMID:15944327)
• Review. TSLP influences the outcome of interactions between dendritic cells and CD4+ thymocytes and T cells in many situations. (PMID:16785889)
• inflammatory mediators IL-1beta and TNF-alpha regulate human TSLP gene expression in an NFkappaB-dependent manner (PMID:17213320)
• TSLP, acting upstream of CD4-positive T cell responses, may provide a functional “missing link” between epithelial cells, Langerhans cells, and T-cell-mediated immunity. (PMID:17320941)
• Collectively, these results suggest that TSLP, as a downstream molecule of TNF-alpha, may be involved in the pathophysiology of inflammatory arthritis. (PMID:17416344)
• human airway smooth muscle cells may play a role in chronic obstructive pulmonary disease airway inflammation via TSLP-dependent pathway (PMID:17513456)
• Human CD4-positive T cells are direct targets for thymic stromal lymphopoietin (TSLP). (PMID:17513717)
• IL-25 produced by innate effector eosinophils and basophils may augment the allergic inflammation by enhancing the maintenance and functions of TSLP-DC activated adaptive Th2 memory cells (PMID:17635955)
• Master switch of allergic inflammation at epithelial cell and dendritic cell interface. Link between TSLP and atopic dermatitis and asthma. Review. (PMID:17666213)
• RSV F protein stimulates TSLP expression in human bronchial epithelial cells mediated partially by p38 and JNK signal pathways. (PMID:17959543)
• Dendritic cells exposed to diesel exhaust particle-treated human bronchial epithelial cells induced Th2 polarization in a thymic stromal lymphopoietin-dependent manner. (PMID:18049884)
• OX40 ligand (OX40L) is a critical in vivo mediator of TSLP-mediated Th2 responses. (PMID:18060034)
• In a sex-stratified analysis, there was significant evidence of linkage to IgE to cockroach on chromosome 5q23; in female subjects,the T allele of single-nucleotide polymorphism rs2289276 in TSLP was associated with reductions in IgE to cockroach (PMID:18244952)
• REVIEW: effect of the functional versatility of hTSLP-activated DCs (hTSLP-DCs) on T cells (PMID:18445339)
• There is distinct airways expression of TSLP and chemokines which preferentially attract T helper (Th) type 1- and Th2-type T cells, and influx of T cells bearing their receptors in asthma and chronic obstructive pulmonary disease. (PMID:18684970)
• TSLP was detected in all samples and the mRNA and protein expression of TSLP is increased significantly in allergic rhinitis nasal mucosa. TSLP production is tightly correlated with IL-4 and severity of allergic rhinitis. (PMID:18720075)
• Data demonstrate that lysophosphatidic acid stimulates thymic stromal lymphopoietin and CCL20 expression in bronchial epithelial cells via CARMA3-mediated NF-kappaB activation. (PMID:18757306)
• A TSLP-driven mouse model of inflammation exhibits many characteristics of human atopic dermatitis, including infiltrate of CD4-positive cells, eosinophils, mast cells; production of Th2 cytokines; and class switching to produce immunoglobulin E. (PMID:18768889)
• Data suggest that functional genetic polymorphism of the TSLP gene appears to contribute to Th2-polarized immunity through higher TSLP production by bronchial epithelial cells in response to viral respiratory infections. (PMID:18787178)
• expression correlates with presence/ severity of lesions in atopic dermatitis patients (PMID:18802341)
• high expression in lungs of patients with asthma; undetectable expression in epithelial cells of patients with Crohn disease (PMID:18802347)
• expression level is increased in patients with asthma (PMID:18802348)
• Inhibition of NF-kappaB-mediated TSLP expression by retinoid X receptor (PMID:18832669)
• thymic stromal lymphopoietin (TSLP) and human DCs plays an essential role in evoking inflammatory Th2 responses in allergy through OX40 ligand expression on DCs. (PMID:18832690)
• Study of pathways engaged in transgenic model of thymic stromal lymphopoietin-driven airway inflammation demonstrates that simultaneous blockade of interleukin (IL)-13 and IL-4 can reverse established asthma-like chronic airway disease. (PMID:18941246)
• Through DC activation, human TSLP and TLR3 ligands promote differentiation of Th17 cells with the central memory T cell phenotype under Th2-polarizing conditions. (PMID:19055649)
• Cytokine milieu modulates release of thymic stromal lymphopoietin from human keratinocytes stimulated with double-stranded RNA. (PMID:19056108)
• The pathogenic phenotype that develops in the transgenic mouse lung in response to TSLP is governed almost exclusively by a TSLP-facilitated adaptive response directed against foreign antigen. (PMID:19155513)
• mast cells are able to store TSLP intracellularly and to produce TSLP following aggregation of FcepsilonRI in the presence of IL-4 (PMID:19164348)
• The data suggest that TSLP plays a role in augmenting, through DC recruitment and activation, the development of Th2-type T cells in allergic inflammation. (PMID:19187393)
• Thymic stromal lymphopoietin as a mediator of crosstalk between bronchial smooth muscles and mast cells. (PMID:19348931)
• A genetic variant in the region of the thymic stromal lymphopoietin gene is associated with the phenotypes of asthma and airway hyperresponsiveness. (PMID:19539984)
• C allele at the TSLP -847C>T polymorphism may increase susceptibility to generalized vitiligo through decreasing TSLP mRNA expression levels. (PMID:19555430)
• TSLP expression is induced in airway epithelial cells by exposure to allergen-derived proteases and PAR-2 is involved in the process. (PMID:19561109)
• The TSLP protein produced in conjunctival epithelial cells plays a role in severe ocular allergy through the activation of dendritic cells and mast cells in synergy with other cytokines (PMID:19741251)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Tslp	ENSMUSG00000024379
rattus_norvegicus	Tslp	ENSRNOG00000058856

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:1855696) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 71 distinct phenotype terms.

Mouse phenotype (MP)	Records
enlarged spleen	3
enlarged lymph nodes	2
increased immunoglobulin level	2
scaly ears	1
decreased hematocrit	1
enlarged heart	1
enlarged liver	1
reddish skin	1
dermatitis	1
spontaneous skin ulceration	1
skin lesions	1
hyperkeratosis	1
mixed cellular infiltration to dermis	1
decreased body weight	1
weight loss	1
abnormal immune system physiology	1
conjunctivitis	1
liver inflammation	1
lung inflammation	1
acanthosis	1
abnormal airway responsiveness	1
abnormal lymph node morphology	1
respiratory system inflammation	1
abnormal immunoglobulin level	1
decreased IgE level	1

+46 more (showing top 25).

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
WDR36	protein-coding	134430
CAMK4	protein-coding	814
TMEM232	protein-coding	642987
SLC25A46	protein-coding	91137

Protein

Protein identifiers

Thymic stromal lymphopoietin — Q969D9 (reviewed: Q969D9)

All UniProt accessions (2): A0A0C4DG43, Q969D9

UniProt curated annotations — full annotation on UniProt →

Function. Cytokine that induces the release of T-cell-attracting chemokines from monocytes and, in particular, enhances the maturation of CD11c(+) dendritic cells. Can induce allergic inflammation by directly activating mast cells. May act as an antimicrobial peptide in the oral cavity and on the skin.

Subunit / interactions. Interacts with a receptor composed of CRLF2 and IL7R. Binding of TSLP to CRLF2/TSLPR is a mechanistic prerequisite for recruitment of IL7R to the high-affinity ternary complex.

Subcellular location. Secreted.

Tissue specificity. Isoform 1 is expressed in a number of tissues including heart, liver and prostate. Isoform 2 is the predominant form in keratinocytes of oral mucosa, skin and in salivary glands. It is secreted into saliva.

Induction. Released by primary epithelial cells in response to certain microbial products, physical injury, or inflammatory cytokines.

Isoforms (2)

UniProt ID	Names	Canonical?
Q969D9-1	1, lfTSLP	yes
Q969D9-2	2, sfTSLP

RefSeq proteins (2): NP_149024, NP_612561 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029189	TSLP	Family
IPR038329	TSLP_sf	Homologous_superfamily

Pfam: PF15216

UniProt features (20 total): helix 11, disulfide bond 3, glycosylation site 2, signal peptide 1, chain 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

5 structures by resolution:

PDB	Title	Method	Resolution (Å)
8QFZ	TSLP-Bicycle complex	X-RAY DIFFRACTION	1.65
5J13	Structural basis for TSLP antagonism by the therapeutic antibody Tezepelumab (MEDI9929 / …	X-RAY DIFFRACTION	2.3
5J11	Structure of human TSLP in complex with TSLPR and IL-7Ralpha	X-RAY DIFFRACTION	2.56
8ZEU	CryoEM structure of GR2002-F(ab’)2: TSLP complex	ELECTRON MICROSCOPY	3.39
5J12	Structure of human TSLP:TSLPR in complex with mouse IL-7Ralpha	X-RAY DIFFRACTION	3.55

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q969D9-F1	78.95	0.47

Antibody-complex structures (SAbDab)

4 antibodies co-crystallized with this protein: 5J13, 8ZEU, TEZEPELUMAB, TILREKIMIG2

Human Protein Atlas

Protein class: Predicted secreted proteins, Predicted intracellular proteins, FDA approved drug targets, Biotech drugs, Human disease related genes

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): golgi apparatus; vesicles

Antibody reliability (HPA): IF uncertain

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (3)

Type	Positions
Disulfide bond	34–110, 69–75, 90–137

Glycosylation sites (2)

Type	Positions
N-linked (glcnac…) asparagine	64, 119

Function

Pathways and Gene Ontology

Reactome pathways

0 curated (TAS) of 4; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

4 pathways:

ID	Pathway	Evidence
R-HSA-1280215	Cytokine Signaling in Immune system	—
R-HSA-168256	Immune System	—
R-HSA-1266695	Interleukin-7 signaling	electronic
R-HSA-449147	Signaling by Interleukins	—

MSigDB gene sets: 192 (showing top): GOBP_REGULATION_OF_CELL_ACTIVATION, CREL_01, BENPORATH_ES_WITH_H3K27ME3, GOBP_ANTIMICROBIAL_HUMORAL_RESPONSE, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, MODULE_255, GOBP_INFLAMMATORY_RESPONSE, GOBP_RESPONSE_TO_PEPTIDE, MENSE_HYPOXIA_UP, MODULE_317, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION, GOBP_CELL_SURFACE_RECEPTOR_SIGNALING_PATHWAY_VIA_JAK_STAT, NFKB_Q6, GOBP_POSITIVE_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS, MARTINEZ_RB1_TARGETS_UP

GO Biological Process (20): positive regulation of cytokine-mediated signaling pathway (GO:0001961), cell surface receptor signaling pathway via JAK-STAT (GO:0007259), positive regulation of cell population proliferation (GO:0008284), cytokine-mediated signaling pathway (GO:0019221), positive regulation of chemokine production (GO:0032722), positive regulation of interleukin-10 production (GO:0032733), positive regulation of interleukin-13 production (GO:0032736), positive regulation of interleukin-5 production (GO:0032754), positive regulation of interleukin-6 production (GO:0032755), positive regulation of mast cell activation (GO:0033005), interleukin-7-mediated signaling pathway (GO:0038111), negative regulation of apoptotic process (GO:0043066), positive regulation of inflammatory response (GO:0050729), defense response to Gram-negative bacterium (GO:0050829), defense response to fungus (GO:0050832), antimicrobial humoral immune response mediated by antimicrobial peptide (GO:0061844), positive regulation of chemokine (C-C motif) ligand 1 production (GO:0071654), positive regulation of granulocyte colony-stimulating factor production (GO:0071657), positive regulation of receptor signaling pathway via STAT (GO:1904894), signal transduction (GO:0007165)

GO Molecular Function (2): cytokine activity (GO:0005125), interleukin-7 receptor binding (GO:0005139)

GO Cellular Component (1): extracellular region (GO:0005576)

Reactome top-level categories

3 top-level categories:

Category	Pathways
Signaling by Interleukins	1
Immune System	1
Cytokine Signaling in Immune system	1

GO top-level categories

52 GO namespaces:

Category	Terms
positive regulation of cytokine production	5
positive regulation of signal transduction	2
cytokine-mediated signaling pathway	2
cell surface receptor signaling pathway via STAT	2
regulation of cytokine-mediated signaling pathway	1
positive regulation of response to cytokine stimulus	1
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
cell surface receptor signaling pathway	1
cellular response to cytokine stimulus	1
chemokine production	1
regulation of chemokine production	1
interleukin-10 production	1
regulation of interleukin-10 production	1
interleukin-13 production	1
regulation of interleukin-13 production	1
interleukin-5 production	1
regulation of interleukin-5 production	1
interleukin-6 production	1
regulation of interleukin-6 production	1
positive regulation of leukocyte activation	1
regulation of mast cell activation	1
mast cell activation	1
cellular response to interleukin-7	1
apoptotic process	1
regulation of apoptotic process	1
negative regulation of programmed cell death	1
inflammatory response	1
positive regulation of defense response	1
positive regulation of response to external stimulus	1
regulation of inflammatory response	1
defense response to bacterium	1
defense response	1
response to fungus	1
antimicrobial humoral response	1
positive regulation of chemokine production	1
chemokine (C-C motif) ligand 1 production	1
regulation of chemokine (C-C motif) ligand 1 production	1
granulocyte colony-stimulating factor production	1
regulation of granulocyte colony-stimulating factor production	1
positive regulation of macrophage colony-stimulating factor production	1
regulation of receptor signaling pathway via STAT	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
receptor ligand activity	1
cytokine receptor binding	1
growth factor receptor binding	1
cellular anatomical structure	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 22 of 24 annotations. The rest are phylogenetic / computational / electronic (IEA).

22 experimentally-supported GO terms:

GO term	NS	Evidence
antimicrobial humoral immune response mediated by antimicrobial peptide	BP	direct assay
cell surface receptor signaling pathway via JAK-STAT	BP	direct assay
cytokine-mediated signaling pathway	BP	direct assay
defense response to Gram-negative bacterium	BP	direct assay
defense response to fungus	BP	direct assay
interleukin-7-mediated signaling pathway	BP	direct assay
negative regulation of apoptotic process	BP	direct assay
positive regulation of cell population proliferation	BP	direct assay
positive regulation of chemokine (C-C motif) ligand 1 production	BP	mutant phenotype
positive regulation of chemokine production	BP	direct assay
positive regulation of cytokine-mediated signaling pathway	BP	direct assay
positive regulation of granulocyte colony-stimulating factor production	BP	mutant phenotype
positive regulation of inflammatory response	BP	mutant phenotype
positive regulation of interleukin-10 production	BP	mutant phenotype
positive regulation of interleukin-13 production	BP	mutant phenotype
positive regulation of interleukin-5 production	BP	mutant phenotype
positive regulation of interleukin-6 production	BP	mutant phenotype
positive regulation of mast cell activation	BP	mutant phenotype
positive regulation of receptor signaling pathway via STAT	BP	direct assay
extracellular region	CC	direct assay
cytokine activity	MF	direct assay
interleukin-7 receptor binding	MF	mutant phenotype

Protein interactions and networks

STRING

showing 15 of 1,542 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TSLP	CRLF2	Q9HC73	944
TSLP	IL33	O95760	917
TSLP	IL5	P05113	884
TSLP	IL13	P35225	884
TSLP	IL7	P13232	867
TSLP	CCL17	Q92583	857
TSLP	IL7R	P16871	848
TSLP	IL4	P05112	820
TSLP	CCL22	O00626	800
TSLP	KLK11	Q9UBX7	793
TSLP	IL31	Q6EBC2	775
TSLP	IL9	P15248	745
TSLP	FLG	P20930	742
TSLP	CD4	P01730	722
TSLP	FLG2	Q5D862	719

IntAct

Human interaction partners of TSLP in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

2 partners by confidence:

Partner	Interaction type	MIscore	Records
IKBKG	direct interaction	0.000	1
PRNP	direct interaction	0.000	1

BioGRID (11 interactions; top human partners by supporting records): APP (Reconstituted Complex; 2 records), ABCA1 (Co-fractionation), ABCA2 (Co-fractionation), ABI2 (Co-fractionation), FBXO7 (Biochemical Activity), IGF2R (Co-fractionation), IGSF3 (Co-fractionation), IKBKG (Reconstituted Complex), PRNP (Reconstituted Complex), WASF1 (Co-fractionation)

SIGNOR signaling

1 signaling interactions:

A	Effect	B	Mechanism
TSLP	up-regulates	CRLF2	binding

Protein complexes (CORUM) (1)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

1 complexes by size:

Complex	Subunits	Members
★ CRLF2-Il7R-TSLP complex	3	CRLF2, IL7R, TSLP

Ligand–receptor pairs (CellPhoneDB) (1)

Curated ligand–receptor partners (cell-cell communication), distinct from the protein–protein interactions above.

1 ligand–receptor pairs:

Partner	This gene’s role	Signaling class
IL7R;CRLF2	ligand

Disease & clinical

Genetic variants

Variant evidence for TSLP: 31 ClinVar records (0 pathogenic / likely pathogenic); 60 GWAS associations.

ClinVar

31 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	27
Likely benign	3
Benign	0

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 22 predictions of 281):

Position(s)	Effect	Δscore	Sites
5:111072886–111072887	acceptor_loss	1.0000	4
5:111072933–111072934	donor_loss	1.0000	5
5:111073486	acceptor_gain	1.0000
5:111073490–111073492	acceptor_gain	1.0000	2
5:111073504	acceptor_gain	1.0000
5:111073646–111073647	donor_loss	1.0000	4
5:111072886–111072887	acceptor_loss	0.9900	2
5:111072934	donor_loss	0.9900
5:111073467	acceptor_gain	0.9900
5:111073491	acceptor_gain	0.9900

AlphaMissense

198 missense substitutions predicted likely pathogenic (of 1,039 scored), across 62 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
F98	8	0.846	0.971
C110	7	0.940	0.973
W148	7	0.926	0.983
C75	7	0.917	0.956
C34	7	0.910	0.945
F31	7	0.899	0.973
C69	7	0.886	0.929
C90	7	0.865	0.925
C137	7	0.854	0.930
F151	7	0.827	0.920
T102	6	0.700	0.817
D35	6	0.666	0.709
F36	5	0.866	0.937
I79	5	0.845	0.966
F84	5	0.834	0.895
Y113	5	0.686	0.744
L76	4	0.844	0.945
R15	4	0.716	0.787
V141	4	0.708	0.789
Y43	4	0.659	0.825

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

1 prognostic cancer types:

Cancer	Prognostic	p-value
Liver Hepatocellular Carcinoma (validation)	favorable	0.000134

Disease associations

OMIM: gene MIM:607003 | disease phenotypes:

GWAS associations

showing 30 of 60 associations:

Study	Trait	p-value
GCST007800_44	Asthma (childhood onset)	7e-94
GCST010043_59	Asthma	8e-81
GCST010042_131	Asthma	3e-57
GCST008916_40	Asthma	1e-51
GCST90014325_69	Asthma	1e-47
GCST009798_73	Asthma	1e-44
GCST009720_23	Asthma	4e-44
GCST007798_133	Asthma	1e-41
GCST007798_134	Asthma	1e-38
GCST005038_30	Allergic disease (asthma, hay fever or eczema)	2e-31
GCST003987_6	Asthma	3e-31
GCST007800_25	Asthma (childhood onset)	2e-30
GCST007798_131	Asthma	2e-29
GCST007798_132	Asthma	2e-29
GCST007443_2	Nasal polyps	4e-29
GCST005038_56	Allergic disease (asthma, hay fever or eczema)	6e-29
GCST007995_18	Asthma (childhood onset)	2e-27
GCST005212_40	Asthma	9e-26
GCST006862_11	Asthma	2e-25
GCST90002381_79	Eosinophil count	6e-24
GCST007941_16	Medication use (adrenergics, inhalants)	4e-23
GCST005038_29	Allergic disease (asthma, hay fever or eczema)	1e-22
GCST007799_2	Asthma (adult onset)	1e-22
GCST004606_54	Eosinophil count	2e-22
GCST006911_25	Asthma (moderate or severe)	2e-22
GCST90027899_3	Eosinophilic esophagitis	6e-22
GCST004600_156	Eosinophil percentage of white cells	4e-21
GCST007564_10	Asthma or allergic disease (pleiotropy)	4e-21
GCST002083_18	Self-reported allergy	2e-20
GCST007562_1	Asthma	2e-20

EFO canonical traits (from GWAS)

9 canonical traits:

EFO ID	Trait name
EFO:0004842	eosinophil count
EFO:0005298	allergic sensitization measurement
EFO:0007991	eosinophil percentage of leukocytes
EFO:0007996	eosinophil percentage of granulocytes
EFO:0007994	neutrophil percentage of granulocytes
EFO:0004847	age at onset
EFO:1002011	adult onset asthma
EFO:0009941	Inhalant adrenergic use measurement
EFO:0009942	Glucocorticoid use measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3712931 (SINGLE PROTEIN)

Drugs by curated mechanism of action (ChEMBL)

Drugs whose curated ChEMBL mechanism of action targets the TSLP protein itself — single-protein targets only (drugs acting on a protein family or complex that merely includes it are excluded). Includes antibodies and oligonucleotides that bioactivity screening does not capture.

1 curated-mechanism drugs:

Drug	Modality	Max phase
TEZEPELUMAB	Antibody	4

PharmGKB: 1 entry (CPIC guideline: no)

Binding affinities (BindingDB)

49 measured of 51 human assays (52 total across all organisms); most potent 49 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CHEMBL5594472	KD	2 nM
CHEMBL5568693	KD	3 nM
CHEMBL5563474	KD	3 nM
CHEMBL5573652	KD	3 nM
CHEMBL5566614	KD	4 nM
CHEMBL5595593	KD	6 nM
CHEMBL5574722	KD	6 nM
CHEMBL5569104	KD	6 nM
CHEMBL5572108	KD	6 nM
CHEMBL5583600	KD	9 nM
CHEMBL5593210	KD	13 nM
CHEMBL5571424	KD	13 nM
CHEMBL5542413	KD	14 nM
CHEMBL5564500	KD	14 nM
CHEMBL5574606	KD	20 nM
CHEMBL5571446	KD	29 nM
CHEMBL5589795	KD	31 nM
CHEMBL5574168	KD	33 nM
CHEMBL5589702	KD	33 nM
CHEMBL5575601	KD	33 nM
CHEMBL5573129	KD	36 nM
CHEMBL5566682	KD	37 nM
CHEMBL5594799	KD	43 nM
CHEMBL5571168	KD	48 nM
CHEMBL5569889	KD	70 nM
CHEMBL5572561	KD	75 nM
CHEMBL5572417	KD	77 nM
CHEMBL5573827	KD	82 nM
CHEMBL5571015	KD	97 nM
CHEMBL5572866	KD	98 nM
CHEMBL5570697	KD	100 nM
CHEMBL5563347	KD	110 nM
CHEMBL5572390	KD	110 nM
CHEMBL5563312	KD	130 nM
CHEMBL5567065	KD	130 nM
CHEMBL5569905	KD	160 nM
CHEMBL5569814	KD	190 nM
CHEMBL5579715	KD	200 nM
CHEMBL5575035	KD	210 nM
CHEMBL5575721	KD	220 nM
CHEMBL5593764	KD	230 nM
CHEMBL5570404	KD	260 nM
CHEMBL5567424	KD	290 nM
CHEMBL5563591	KD	410 nM
CHEMBL5572000	KD	470 nM
CHEMBL5567113	KD	664 nM
CHEMBL5564963	KD	900 nM
CHEMBL5567325	KD	1100 nM
CHEMBL5572731	KD	1500 nM

ChEMBL bioactivities

50 potent at pChembl≥5 of 50 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.70	Kd	2	nM	CHEMBL5594472
8.52	Kd	3	nM	CHEMBL5568693
8.52	Kd	3	nM	CHEMBL5563474
8.52	Kd	3	nM	CHEMBL5573652
8.40	Kd	4	nM	CHEMBL5566614
8.22	Kd	6	nM	CHEMBL5595593
8.22	Kd	6	nM	CHEMBL5574722
8.22	Kd	6	nM	CHEMBL5569104
8.22	Kd	6	nM	CHEMBL5572108
8.05	Kd	9	nM	CHEMBL5583600
7.89	Kd	13	nM	CHEMBL5593210
7.89	Kd	13	nM	CHEMBL5571424
7.85	Kd	14	nM	CHEMBL5542413
7.85	Kd	14	nM	CHEMBL5564500
7.70	Kd	20	nM	CHEMBL5574606
7.54	Kd	29	nM	CHEMBL5571446
7.51	Kd	31	nM	CHEMBL5589795
7.48	Kd	33	nM	CHEMBL5574168
7.48	Kd	33	nM	CHEMBL5589702
7.48	Kd	33	nM	CHEMBL5575601
7.44	Kd	36	nM	CHEMBL5573129
7.43	Kd	37	nM	CHEMBL5566682
7.37	Kd	43	nM	CHEMBL5594799
7.32	Kd	48	nM	CHEMBL5571168
7.28	Kd	52	nM	CHEMBL5564182
7.16	Kd	70	nM	CHEMBL5569889
7.12	Kd	75	nM	CHEMBL5572561
7.11	Kd	77	nM	CHEMBL5572417
7.09	Kd	82	nM	CHEMBL5573827
7.01	Kd	98	nM	CHEMBL5572866
7.01	Kd	97	nM	CHEMBL5571015
7.00	Kd	100	nM	CHEMBL5570697
6.96	Kd	110	nM	CHEMBL5563347
6.96	Kd	110	nM	CHEMBL5572390
6.89	Kd	130	nM	CHEMBL5563312
6.89	Kd	130	nM	CHEMBL5567065
6.80	Kd	160	nM	CHEMBL5569905
6.72	Kd	190	nM	CHEMBL5569814
6.70	Kd	200	nM	CHEMBL5579715
6.68	Kd	210	nM	CHEMBL5575035
6.66	Kd	220	nM	CHEMBL5575721
6.64	Kd	230	nM	CHEMBL5593764
6.58	Kd	260	nM	CHEMBL5570404
6.54	Kd	290	nM	CHEMBL5567424
6.39	Kd	410	nM	CHEMBL5563591
6.33	Kd	470	nM	CHEMBL5572000
6.18	Kd	664	nM	CHEMBL5567113
6.05	Kd	900	nM	CHEMBL5564963
5.96	Kd	1100	nM	CHEMBL5567325
5.82	Kd	1500	nM	CHEMBL5572731

PubChem BioAssay actives

50 with measured affinity, of 114 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12,21-bis(3-amino-3-oxopropyl)-42-carbamoyl-39-[(3-chloro-4-fluorophenyl)methyl]-33-[3-[(N,N-dimethylcarbamimidoyl)amino]propyl]-18-(2,2-dimethylpropyl)-15,30-bis[(1-methylindol-3-yl)methyl]-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-24-yl]acetic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0020	uM
3-[(9R,12S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-18-(2,2-dimethylpropyl)-39-[(4-fluorophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0030	uM
3-[(9R,12S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-42-carbamoyl-24-(carboxymethyl)-33-[3-[(N,N-dimethylcarbamimidoyl)amino]propyl]-18-(2,2-dimethylpropyl)-39-[(4-fluorophenyl)methyl]-15,30-bis[(1-methylindol-3-yl)methyl]-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0030	uM
2-[(9R,12S,18S,21S,27R,30S,33S,39S,42R)-9-acetamido-21-(3-amino-3-oxopropyl)-42-carbamoyl-33-[3-[(N,N-dimethylcarbamimidoyl)amino]propyl]-18-(2,2-dimethylpropyl)-39-[(4-fluorophenyl)methyl]-11,12,23-trimethyl-15,30-bis[(1-methylindol-3-yl)methyl]-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-24-yl]acetic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0030	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-39-[(3-chloro-4-fluorophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0040	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-39-[(4-fluorophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0060	uM
2-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12,21-bis(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-39-[(4-fluorophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-24-yl]acetic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0060	uM
2-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-21-(3-amino-3-oxopropyl)-42-carbamoyl-33-[3-[(N,N-dimethylcarbamimidoyl)amino]propyl]-18-(2,2-dimethylpropyl)-39-[(4-fluorophenyl)methyl]-11,12-dimethyl-15,30-bis[(1-methylindol-3-yl)methyl]-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-24-yl]acetic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0060	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-39-[(4-chlorophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0060	uM
2-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12,21-bis(3-amino-3-oxopropyl)-42-carbamoyl-33-[3-[(N,N-dimethylcarbamimidoyl)amino]propyl]-39-[(4-fluorophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-24-yl]acetic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0090	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-42-carbamoyl-24-(carboxymethyl)-33-[3-[(N,N-dimethylcarbamimidoyl)amino]propyl]-39-[(4-fluorophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-11,12-dimethyl-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0130	uM
2-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-42-[[(2S)-1-amino-1-oxopropan-2-yl]carbamoyl]-21-(3-amino-3-oxopropyl)-33-[3-[(N,N-dimethylcarbamimidoyl)amino]propyl]-18-(2,2-dimethylpropyl)-39-[(4-fluorophenyl)methyl]-11,12-dimethyl-30-[(1-methylindol-3-yl)methyl]-15-(naphthalen-1-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-24-yl]acetic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0130	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-42-[[(2S)-1-amino-1-oxopropan-2-yl]carbamoyl]-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-24-(carboxymethyl)-39-[(4-fluorophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0140	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-39-[(3-chlorophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0140	uM
3-[(9R,12S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-42-carbamoyl-24-(carboxymethyl)-33-[3-[(N,N-dimethylcarbamimidoyl)amino]propyl]-39-[(4-fluorophenyl)methyl]-30-(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-15-(naphthalen-1-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0200	uM
(3S)-4-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-[[2-[[(2S)-2-[[(2S)-2-[[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-12-(3-amino-3-oxopropyl)-9-[[(2S)-2-aminopropanoyl]amino]-39-benzyl-33-(3-carbamimidamidopropyl)-21-(2-carboxyethyl)-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontane-42-carbonyl]amino]propanoyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-4-oxobutanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0290	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-18-(2,2-dimethylpropyl)-15,30-bis(1H-indol-3-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0310	uM
(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[(2-aminoacetyl)amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-[[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-42-[[(2S)-1-amino-1-oxopropan-2-yl]carbamoyl]-12-(3-amino-3-oxopropyl)-39-benzyl-33-(3-carbamimidamidopropyl)-21-(2-carboxyethyl)-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-9-yl]amino]-5-oxopentanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0330	uM
(9R,12R,15S,18S,21S,24R,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-21-(2-carboxyethyl)-24-(carboxymethyl)-39-[(4-fluorophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontane-42-carboxylic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0330	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-39-(naphthalen-1-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0330	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-42-[[(2S)-1-amino-1-oxopropan-2-yl]carbamoyl]-12-(3-amino-3-oxopropyl)-24-(carboxymethyl)-33-[3-[(N,N-dimethylcarbamimidoyl)amino]propyl]-39-[(4-fluorophenyl)methyl]-30-(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-15-(naphthalen-1-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0360	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-39-(naphthalen-2-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0370	uM
(3S)-4-amino-3-[[(2S)-2-[[(2S)-1-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-12-(3-amino-3-oxopropyl)-9-[[(2S)-2-aminopropanoyl]amino]-39-benzyl-33-(3-carbamimidamidopropyl)-21-(2-carboxyethyl)-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontane-42-carbonyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0430	uM
(4S)-4-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-42-[[(2S)-1-amino-1-oxopropan-2-yl]carbamoyl]-12-(3-amino-3-oxopropyl)-39-benzyl-33-(3-carbamimidamidopropyl)-21-(2-carboxyethyl)-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-9-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0480	uM
3-[(1S,4S,7R,23R,26S,32S,35S,38R,41S,44S,47S,52Z)-7-acetamido-4-(3-amino-3-oxopropyl)-23-carbamoyl-41-(carboxymethyl)-26-[(4-fluorophenyl)methyl]-35-(1H-indol-3-ylmethyl)-47-(2-methylpropyl)-3,6,12,18,25,28,31,34,37,40,43,46,49,60-tetradecaoxo-9,21,57-trithia-2,5,13,15,17,24,27,30,33,36,39,42,45,48-tetradecazatetracyclo[30.17.6.515,38.113,17]henhexacont-52-en-44-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0520	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-18-(cyclopentylmethyl)-15,30-bis(1H-indol-3-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0700	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-42-[[(2S)-1-amino-1-oxopropan-2-yl]carbamoyl]-12-(3-amino-3-oxopropyl)-9-[[(2S)-2-aminopropanoyl]amino]-39-benzyl-33-(3-carbamimidamidopropyl)-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0750	uM
3-[(1S,4S,7R,23R,26S,32S,35S,38R,41S,44S,47S)-7-acetamido-4-(3-amino-3-oxopropyl)-23-carbamoyl-41-(carboxymethyl)-26-[(4-fluorophenyl)methyl]-35-(1H-indol-3-ylmethyl)-47-(2-methylpropyl)-3,6,12,18,25,28,31,34,37,40,43,46,49,60-tetradecaoxo-9,21,57-trithia-2,5,13,15,17,24,27,30,33,36,39,42,45,48-tetradecazatetracyclo[30.17.6.515,38.113,17]henhexacontan-44-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0770	uM
3-[(1S,4S,7R,23R,26S,32S,35S,38R,41S,44S,47S)-7-acetamido-4-(3-amino-3-oxopropyl)-23-carbamoyl-41-(carboxymethyl)-26-[(4-fluorophenyl)methyl]-35-(1H-indol-3-ylmethyl)-47-(2-methylpropyl)-3,6,12,18,25,28,31,34,37,40,43,46,49,62-tetradecaoxo-9,21,59-trithia-2,5,13,15,17,24,27,30,33,36,39,42,45,48-tetradecazatetracyclo[30.17.8.515,38.113,17]trihexacontan-44-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0820	uM
3-[(1S,4S,7R,23R,26S,32S,35S,38R,41S,44S,47S,52E)-7-acetamido-4-(3-amino-3-oxopropyl)-23-carbamoyl-41-(carboxymethyl)-26-[(4-fluorophenyl)methyl]-35-(1H-indol-3-ylmethyl)-47-(2-methylpropyl)-3,6,12,18,25,28,31,34,37,40,43,46,49,60-tetradecaoxo-9,21,57-trithia-2,5,13,15,17,24,27,30,33,36,39,42,45,48-tetradecazatetracyclo[30.17.6.515,38.113,17]henhexacont-52-en-44-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0970	uM
3-[(9R,12S,15S,18S,21S,24S,27S,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0980	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-18-(cyclopropylmethyl)-15,30-bis(1H-indol-3-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.1000	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-18-(cyclohexylmethyl)-15,30-bis(1H-indol-3-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.1100	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-42-carbamoyl-24-(carboxymethyl)-33-[3-[(N,N-dimethylcarbamimidoyl)amino]propyl]-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.1100	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-18-propyl-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.1300	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-39-[(4-methylphenyl)methyl]-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.1300	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-42-carbamoyl-33-[3-(carbamoylamino)propyl]-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.1600	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-39-[(2-fluorophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.1900	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-18-(2,2,2-trifluoroethyl)-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.2000	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-33-(4-carbamimidamidobutyl)-42-carbamoyl-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.2100	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-39-(cyclohexylmethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.2200	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-24-(2-amino-2-oxoethyl)-42-[[(2S)-1-amino-1-oxopropan-2-yl]carbamoyl]-9-[[(2S)-2-aminopropanoyl]amino]-39-benzyl-33-(3-carbamimidamidopropyl)-12-(1H-imidazol-4-ylmethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.2300	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-39-[(4-cyanophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.2600	uM
3-[(9R,12S,15S,18S,21S,24S,27S,30S,33S,39S,42R)-9-acetamido-24-(2-amino-2-oxoethyl)-39-benzyl-33-(3-carbamimidamidopropyl)-42-carbamoyl-12-(1H-imidazol-4-ylmethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.2900	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-39-(thiophen-3-ylmethyl)-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.4100	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-33-(2-carbamimidamidoethyl)-42-carbamoyl-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.4700	uM
3-[(1S,4S,7R,23R,26S,32S,35S,38R,41S,44S,47S)-7-acetamido-4-(3-amino-3-oxopropyl)-23-carbamoyl-41-(carboxymethyl)-26-[(4-fluorophenyl)methyl]-35-(1H-indol-3-ylmethyl)-47-(2-methylpropyl)-3,6,12,18,25,28,31,34,37,40,43,46,49,61-tetradecaoxo-9,21,58-trithia-2,5,13,15,17,24,27,30,33,36,39,42,45,48-tetradecazatetracyclo[30.17.7.515,38.113,17]dohexacontan-44-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.6640	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-15,33-bis(but-3-enyl)-42-carbamoyl-24-(carboxymethyl)-39-[(4-fluorophenyl)methyl]-30-(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.9000	uM
3-[(9R,12S,15S,18S,21S,24S,27R,31S,34S,40S,43R)-9-acetamido-12-(3-amino-3-oxopropyl)-40-benzyl-43-carbamoyl-24-(carboxymethyl)-15,31-bis(1H-indol-3-ylmethyl)-34-methyl-18-(2-methylpropyl)-4,10,13,16,19,22,25,29,32,35,38,41,48,51-tetradecaoxo-7,45,54-trithia-1,3,11,14,17,20,23,26,30,33,36,39,42,49-tetradecazatricyclo[25.23.4.13,49]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	1.1000	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-18-ethyl-15,30-bis(1H-indol-3-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	1.5000	uM

CTD chemical–gene interactions

91 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Particulate Matter	decreases reaction, increases expression, decreases expression, increases abundance, increases secretion (+1 more)	9
Valproic Acid	affects cotreatment, increases expression, affects expression	7
bisphenol A	decreases expression, increases expression, increases methylation, affects expression	3
Acetaminophen	affects cotreatment, increases expression, decreases expression	3
Vehicle Emissions	decreases reaction, increases expression, affects reaction, increases secretion	3
Tetradecanoylphorbol Acetate	increases expression, increases secretion, affects cotreatment, decreases reaction	3
sodium arsenite	decreases expression, increases expression	2
Acetylcysteine	decreases reaction, increases expression	2
Air Pollutants	decreases expression, increases abundance, increases expression	2
Benzo(a)pyrene	affects methylation, increases expression	2
Estradiol	increases expression, increases reaction, affects cotreatment, decreases expression	2
Lipopolysaccharides	decreases reaction, increases secretion, increases expression, affects cotreatment	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Poly I-C	increases expression, increases reaction, affects cotreatment, decreases reaction	2
Cyclosporine	increases expression	2
Aflatoxin B1	affects expression, decreases methylation, increases expression	2
Glupearl 19S	decreases reaction, increases expression	1
helenalin	decreases reaction, increases expression, affects cotreatment	1
parthenolide	decreases reaction, increases expression	1
naringin	increases expression, affects cotreatment, decreases reaction	1
kaempferol	decreases reaction, increases expression, increases secretion	1
chelex	decreases reaction, increases secretion	1
ethyl-p-hydroxybenzoate	increases expression	1
arsenite	increases methylation	1
mono-(2-ethylhexyl)phthalate	decreases methylation, increases abundance	1
pyrrolidine dithiocarbamic acid	decreases reaction, increases expression	1
nickel chloride	increases expression, increases reaction	1
butylbenzyl phthalate	decreases methylation, increases abundance	1
ceric oxide	affects cotreatment, increases expression	1
hydroquinone	increases expression	1

ChEMBL screening assays

12 unique, capped per target: 12 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4047224	Binding	Inhibition of human N-terminal flag-tagged TSLP/human C-terminal octa histidine-tagged TSLPR interaction at 0.1 mM after 16 hrs by ELISA based spectrophotometric analysis	Synthesis and biological evaluation of peptide-derived TSLP inhibitors. — *Bioorg Med Chem Lett*

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D9V4	Ubigene HEK293 TSLP KO	Transformed cell line	Female

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for TSLP across ~30M SureChEMBL compounds — explore on Sugi Predict.